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VINYL CHLORIDE-DIET INTERACTIONS IN LIVER DISEASE: 
POTENTIAL ROLES OF AUTOPHAGY AND ENERGY MANAGEMENT 
Anna L. Lang 
May 12, 2016 
 Vinyl chloride (VC) is a prevalent environmental toxicant that has been 
shown to cause liver injury at high, occupational exposures. However, most studies 
have not addressed interactions of low doses with risk-modifying factors. This 
study aims to explore low-level VC metabolite exposure interactions with other 
potential risk-modifying factors and their effect on underlying liver disease. We 
examined sub-hepatotoxic effects of a VC metabolite (chloroethanol, CE) in two 
murine models of liver injury using ethanol and lipopolysaccharide (LPS). In both, 
CE significantly enhanced liver injury when compared to either ethanol or LPS 
alone. Previous studies have shown an increase in mTOR activity with CE alone. 
Here, we used a pharmacologic inhibitor of mTOR, rapamycin, to study its effect 
on injury progression. Indeed, the addition of rapamycin significantly attenuated 
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I. Vinyl Chloride  
 Vinyl chloride monomer (VC) is a pervasive environmental organochlorine 
toxicant. It is ranked #4 on the CDC’s Agency for Toxic Substances and Disease 
Registry (ATSDR) Substance Priority List;(1) with an annual production recently 
estimated at 27 million metric tons (2). VC is used in industry to produce polyvinyl 
chloride (PVC), a plastic involved in commercial production. Facilities that 
manufacture PVC products emit VC gas into the air as a waste product. VC is also 
present as a solvent at many EPA Superfund sites across the United States. Aside 
from being a direct contaminant at these sites, VC is a degradation product of other 
chlorinated chemicals such as trichloroethylene (TCE; ATSDR rank #16) 
tetrachloroethylene (PCE; ATSDR rank #33) and dichloroethene (DCE; ATSDR 
rank #216) via soil microorganisms (3). Owing to its widespread prevalence, VC is 
present in landfill leachates and many military Superfund sites across the country. 
For example, up to 1,000,000 military, civilian personnel, and their families were 
exposed to VC at Camp Lejeune, NC alone (3). Additionally, more than 80,000 
American chemical workers have been occupationally exposed to VC (4, 5). 
VC is present in the air surrounding production facilities at significant 




contaminated groundwater. Residential areas surrounding both manufacturing and 
Superfund sites are susceptible to VC migrating through soil and home foundations 
where it readily volatilizes to enter showers, basements, and living spaces where 
these vapors can recirculate (4, 5). Due to the high risk of low-level human 
exposure in residential areas around VC-using facilities, understanding the effects 
of this toxicant on human health is necessary, but current knowledge is sparse on 
low-level VC exposure.  
The major target of VC exposure is the liver. VC is a known hepatotoxicant 
and at high, occupational levels of exposure, VC can cause steatosis (fat 
accumulation), inflammation (steatohepatitis), fibrosis, and necrosis (6). Recently, 
a pathology unique to VC exposure has been described, toxicant-associated 
steatohepatitis (TASH), in chemical plant workers occupationally exposed to VC 
(7, 8). These individuals showed most of the typical clinical signs of liver injury. 
Within that cohort, 84% of patients exhibited hepatic steatosis and 85% exhibited 
steatohepatitis. However, of the patients with steatohepatitis, only 55% went on to 
develop fibrosis. Interestingly, plasma transaminase levels, which are typically 
elevated with liver injury, were at normal levels in these individuals (8). Although 
the effects of high level VC exposure have been studied, the effects of low level 
exposure and its interactions with other risk-modifying factors, such as diet or 
alcohol consumption, on hepatic and overall health have not been determined. 
Therefore, it is crucial that these knowledge gaps are filled.  




The liver is a major site of nutrient metabolism, detoxification, and is crucial 
to maintaining a healthy digestive system. Liver function is determined not only by 
genetics, but by diet, alcohol consumption, and toxicant exposure. As such, the 
liver is susceptible to injury from a variety of agents. The most common 
manifestation of liver damage is fatty liver disease (FLD), which is characterized 
by an accumulation of triglycerides in the liver (9). Depending on the source of the 
insult, it can be termed alcoholic liver disease (ALD) or non-alcoholic fatty liver 
disease (NAFLD). Both diseases share similar pathological manifestations, but 
have unique etiologies. In general, liver disease is a spectrum of pathologies 
ranging from benign steatosis to active inflammation (steatohepatitis) to fibrosis, 
cirrhosis (10), and potentially, hepatocellular carcinoma (11, 12). Processes 
hypothesized that contribute to the initiation and progression of FLD include 
lipotoxicity, (13) oxidative stress (13, 14) and inflammation (15, 16).  
Although many people have FLD, only a fraction of that population will 
progress from steatosis to a more severe form of the disease, such as 
steatohepatitis (17, 18). Many factors play a role in determining severity of disease 
and its progression, including genetics and environmental agents. Due to an 
increase in triglycerides within hepatocytes, regular fatty acid metabolism is 
disrupted, leading to alterations in other metabolic pathways such as protein and 
carbohydrate metabolism (19).These changes on a molecular level cause the liver 
to be more susceptible to insult from a second agent, such as VC. The effects of 




 It is known that the liver becomes susceptible to injury from a second agent 
after changes occur in response to a first agent (20, 21). For example, Yang et al. 
(21) demonstrated that livers from genetically obese (fa/fa) rats have enhanced 
sensitivity to inflammation produced by the injection of bacterial lipopolysaccharide 
(LPS) compared to their lean littermates; this exacerbation of liver damage is 
characterized by a more robust inflammatory response and enhanced cell death. 
Recent studies from our group have demonstrated that sub-hepatotoxic doses of 
a major VC metabolite, chloroethanol (CE), enhanced liver injury in response to 
LPS administration in a murine model (22). In that study, animals who received CE 
alone showed no histological changes in their liver tissue morphology. However, 
on a protein level, many key metabolic enzymes were altered. There was also an 
increase in steatosis and a decrease in glycogen stores, indicating alterations in 
lipid and carbohydrate metabolism. The combination of both CE and LPS caused 
enhanced damage when compared to either exposure alone as characterized by 
enhanced inflammatory cytokine expression, histology and gross liver damage 
(22). This study demonstrates a proof-of-concept that low levels of a VC metabolite 
can enhance liver injury caused by LPS administration. Alterations in hepatocyte 
metabolic enzymes and pathways that are not overly toxic can sensitize the liver 
to be more susceptible to an insult from another agent. Although the hypothesis of 
multiple “hits” in liver injury progression is not a new one, the application of this 
paradigm to explore low-level VC exposure and underlying liver damage is novel.  




Millions of people worldwide consume alcoholic beverages. According to 
the World Health Organization (WHO), 3.3 million (5.9%) of deaths worldwide are 
due to the harmful use of alcohol (23). ALD encompasses several pathologies from 
mild fat accumulation (steatosis), liver inflammation (alcoholic steatohepatitis; 
ASH), to severe fibrosis, and cirrhosis (end-stage liver disease). Cirrhosis of the 
liver is the 12th leading cause of death in the United States and in 2013, nearly 
50% of all liver disease-related deaths were caused by ALD (24).  
As the liver is the primary location of alcohol metabolism, it is the organ 
most affected by alcohol-induced injury. Alcohol is metabolized via alcohol 
dehydrogenase (ADH1), mitochondrial aldehyde dehydrogenase (ALDH2), and 
CYP2E1. A majority of its detrimental effects are a result of its toxic metabolite, 
acetaldehyde, accumulation, induction of an inflammatory response, and oxidative 
stress (25).  
In ALD, steatosis can be caused directly by ethanol metabolites’ disruption 
of the balance between NAD+ and NADH, leading to inhibition of β-oxidation and 
an accumulation of free fatty acids (FFA) and triglycerides (25). Alcohol exposure 
can also alter transcription factors that mediate lipid-metabolizing enzymes. For 
example, acetaldehyde can directly upregulate sterol regulatory element-binding 
protein 1c (SREBP-1c) resulting in an increase in lipogenesis. Conversely, 
acetaldehyde interacts with the DNA binding domain of peroxisome proliferator 
activator protein alpha (PPARα), which inhibits the breakdown of FFA via β-
oxidation (18). Combined, the result is an increase of lipids within the tissue. 




response, particularly the cytokine tumor necrosis factor alpha (TNFα). Upon 
stimulation by alcohol consumption, TNFα is released from the liver’s resident 
macrophages, known as Kupffer cells. It is upregulated and is involved in tissue 
damage in response to alcohol exposure (26). The production of TNFα results in 
recruitment of other inflammatory cells, such as neutrophils, as their infiltration into 
tissue results in a more pronounced inflammatory response (18). 
The combination of increased hepatic lipids and increased cytokine and 
inflammatory cell recruitment allows for a cyclic pattern of liver damage. If alcohol 
consumption continues, injury worsens and is a risk factor for developing more 
serious injury. Due to the fact that VC and alcohol share several mechanisms of 
liver injury, alcohol consumption may be a risk factor for developing more serious 
liver disease when co-exposed with VC.  
B. Obesity and the liver 
Over 30% of US adults are obese (BMI ≥ 30) with another >30% being 
overweight (BMI = 25-30) (27).This metabolic syndrome is characterized by insulin 
resistance, hypertension, and dyslipidemia (28). Due to overconsumption of 
dietary fats, NAFLD is a major hepatic manifestation of obesity and it was recently 
estimated that 25% of the global population has NAFLD (29). Hepatic steatosis 
occurs when the balance between fatty acid synthesis and uptake is greater than 
its oxidation (30). This causes a disruption in energy homeostasis and an 
accumulation of lipid droplets to occur within the liver tissue. NAFLD is also 




resistance and type 2 diabetes, and can be mediated by the inflammatory 
response (31). 
Within the past decade, the perceived role of adipocytes has shifted from 
simple lipid storing vessels to more complex mediators of metabolic, hormonal, 
and inflammatory responses (32). Obesity causes an increase in the size of 
adipocytes within adipose tissue and immune cells, such as macrophages, are 
able to infiltrate into the adipose tissue and release cytokines such as TNFα and 
interleukin-6  (IL-6) (33, 34), which cause further stress and are able to travel 
through circulation and exert effects on the liver and other organs. In addition to 
the cytokines being released from the adipose tissue, an increase in hepatic 
adiposity also results in an increase in hepatic pro-inflammatory cytokine release. 
These cytokines, like TNFα, activate Kupffer cells, which then release more 
inflammatory signals and cause tissue damage (35). These metabolic changes 
within hepatocytes, such as lipid accumulation, make these cells more susceptible 
to insults from other factors and may result in exacerbated liver injury upon co-
exposure with toxicants, such as VC.  
III. VC Mechanism 
A. VC metabolism 
As mentioned previously, VC is metabolized by many of the same enzymes 
that are involved in alcohol metabolism. After exposure via inhalation, absorption 
is rapid and distribution is widespread. Due to the fact that the enzymes involved 
in VC metabolism are primarily located in the liver, it is the most sensitive to VC 




intermediates which all follow Michaelis-Menten enzyme kinetics (36). The first 
pathway involves microsomal mixed function oxidases, primarily CYP2E1, which 
oxidizes VC to 2-chloroethylene oxide, which is then conjugated to glutathione and 
excreted. An alternate pathway of VC metabolism is oxidation to 2-chloroethanol. 
2-chloroethanol can then enter into the same pathway as ethanol metabolism. It is 
transformed into 2-chloroacetaldehye by alcohol dehydrogenase. Aldehyde 
dehydrogenase converts 2-chloroacetaldehyde into chloroacetic acid which is then 
conjugated to glutathione and excreted in urine, ultimately, as thioacetic acid (37). 
VC is inhaled and absorbed through the lungs and its half-life is relatively 
short, being only a few hours. Therefore, it is not likely that VC gas directly 
damages tissue. Its two main reactive metabolites, chloroethanol (CE) and 
chloroactealdehye (CAA), are able to enter cells and cause damage. Once inside 
the cell, VC metabolites are able to generate reactive oxygen and nitrogen species 
(ROS/RNS) and form protein adducts. These then go on to further damage the 
cells by causing oxidative damage, increasing inflammatory cytokine recruitment 
(22), and increasing endoplasmic reticulum (ER) stress.  
B. VC metabolites damage mitochondria 
Mitochondria are essential to the health of all cells as they produce ATP 
and regulate major cell death pathways such as apoptosis and necrosis. 
Mitochondria respond dynamically to stress, nutritional status, and environmental 
signals. It has been hypothesized that the VC metabolite, CAA, inhibits oxidative 
phosphorylation in mitochondria (38, 39) and our group has recently shown that 




decreases mitochondrial membrane potential in a concentration-dependent 
manner, and with increasing concentrations, decreases plasma membrane 
potential as well. This finding was corroborated by cellular bioenergetics analyses 
that showed a decrease in ATP production and decreased oxygen consumption 
rate with increasing CAA concentrations (22). 
Another aspect of mitochondrial damage besides impaired function is the 
accumulation and elimination of damaged mitochondria. This is accomplished by 
the complex process of autophagy.  
C. Autophagy  
Autophagy is the intracellular process of “self-eating” or degradation of 
macromolecules and organelles during times of starvation or stress to provide 
nutrients or to protect the cell. Autophagy is a highly conserved process and as 
such so are the proteins involved. Several autophagy related genes (Atg’s) have 
been identified along with associated proteins which aid in the degradative process 
(40, 41). There are four main phases of autophagy (Figure 1). The first involves 
initiation and formation of the autophagosome. It begins as an isolated membrane 
portion (the phagophore) from the ER or golgi apparatus (42). Through nucleation 
and expansion of the membrane, the phagophore becomes an autophagosome; a 
double membraned structure that engulfs targeted macromolecules, proteins, or 
organelles for degradation. The autophagosome matures and fuses with a 
lysosome, releasing its contents for enzymatic degradation (43).  
Autophagy is crucial for normal cell homeostasis and has been shown to be 










Figure 1. Scheme of autophagic pathway. The main stages of autophagy are 
depicted. Autophagy begins with introduction or initiation of the process. This is 
followed by nucleation, phagophore formation, and autophagosome expansion. 








to be protective (45-47) while its inhibition has been associated with increased liver 
damage (48, 49).  One probable mechanism of its protective effects is the removal 
of damaged organelles, such as mitochondria (mitophagy) (50, 51). If the affected 
cells are unable to clear and degrade damaged mitochondria, their accumulation 
would add to the cellular injury and further impair normal cell function.  
mTOR, (mechanistic target of rapamycin) is a major regulator of autophagy. 
With mTOR being the major sensor for nutritional status of the cell, its activation 
blocks initiation of autophagy while mTOR inhibition allows autophagy to proceed 
(52). As mentioned previously, our group recently showed that mTOR is activated 
in mice administered VC metabolites alone. We hypothesize that 
pharmacologically inhibiting mTOR with rapamycin would allow us to determine if 
autophagy inhibition is involved in liver damage caused by VC metabolite 
exposure. 
IV. Overall significance 
 VC is present in the ambient air and ground water surrounding chemical 
and PVC production facilities, making residents living in those areas at risk for low-
level VC exposure. Many of the at-risk areas are urbanized and of a lower 
socioeconomic status than more suburban residential areas. Other risk factors 
associated with highly urban populations are an increased risk for alcohol 
consumption and a high fat diet resulting in being overweight or obese. Both of 
these factors cause changes on the molecular level in the liver, such as steatosis, 




There is a knowledge gap regarding co-exposure of underlying liver disease 
such as ALD or NAFLD and the effects of low-level, subclinical VC exposure. 
Therefore, the goals of the current work are two-fold: a) to determine whether VC 
exposure may be acting to enhance liver injury in underlying ALD and b) to 
determine the role of mTOR in liver injury progression caused by VC exposure and 
whether or not activation of autophagy could have protective effects in an 

















MATERIAL AND METHODS  
I. Animals and Treatments 
Eight week old, male C57BL/6J mice from Jackson Laboratory (Bar Harbor, ME) 
were housed in a pathogen-free barrier facility accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care, and procedures were 
approved by the local Institutional Animal Care and Use Committee.  
A. Acute-on-chronic alcohol exposure  
Mice were fed either an ethanol-containing Lieber-DeCarli diet or an iso-calorically 
matched control diet. Because of the relatively high caloric content of ethanol, pair-
fed control animals received an iso-caloric control diet; the calories in the iso-
caloric diet were matched by adding a calorie equivalent of maltose-dextrin. During 
the exposure period, animals were housed in pairs in shoebox cages in a room 
held at 75˚F. Diet was provided in vacuum tubes and replaced between 3 and 5 
pm daily. Both ethanol-fed animals and their pair-fed counterparts received control 
diet for the first five days of liquid diet feeding to allow acclimation to the liquid diet 
feeders. On the sixth day, ethanol-fed animals received diet containing 5% (vol/vol) 
ethanol. They continued to receive the ethanol-containing diet for 10 days. On the 
eleventh day, the two diet groups were further separated into additional groups 
that either received a bolus gavage of chloroethanol (CE; 50 mg/kg) or vehicle 




determined by others to not directly cause liver damage (54) and was validated 
(22); mice were ethanol fasted for 4 hours prior to oral gavage and were sacrificed 
4, 9, or 24 hours later (Figure 2A). 
B. Rapamycin administration  
Mice were administered CE (50 mg/kg) via oral gavage. One hour after, rapamycin 
(1mg/kg, i.p., LC Laboratories, Woburn, MA,) was administered. 24 hours after CE 
administration, mice were administered LPS (E. Coli, 10 mg/kg, i.p., Sigma, St. 
Louis, MO) and sacrificed 24 hours later (Figure 2B). 
C. Sample collection 
At the time of sacrifice, animals were anesthetized with ketamine/xylazine (100/15 
mg/kg, i.p.). Blood was collected from the vena cava just prior to sacrifice 
(exsanguination), and citrated plasma was stored at -80°C for further analysis.  
Portions of liver tissue were snap-frozen in liquid nitrogen, embedded in frozen 


















Figure 2. Timelines of experiments. Panel A shows the NIAAA model timeline 
modified with the CE bolus gavage on the eleventh day. Panel B depicts the 
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II. Biochemical Analysis 
Plasma activity levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were determined spectrophotometrically using standard 
kits (Thermotrace, Melbourne, Australia). 
III. Histology  
A. General Morphology  
Formalin fixed, paraffin embedded liver tissue was cut at 5 μm and mounted on 
charged glass slides. Sections were deparaffinized with Citrisolv (Fisher Scientific, 
Waltham, MA) and rehydrated through addition of graded ethanol solutions. 
Sections were then stained with hematoxylin and eosin (H&E). After staining, 
samples were dehydrated through graded alcohol, washed in Citrisolv and then 
mounted with Permount (Fisher, Waltham, MA). 
B. Neutrophil accumulation 
Neutrophil accumulation in liver tissue was measured using chloracetate esterase 
(CAE) staining. Briefly, formalin fixed, paraffin embedded liver tissue was cut at 5 
μm and mounted on charged glass slides. Sections were deparaffinized with 
Citrisolv (Fisher, Waltham, MA) and rehydrated through addition of graded 
solutions of ethanol. Tissue specimens were incubated in a solution of napthol AS-
D chloroacetate (1 mg/ml) in N,N-dimethylformamide, with 4% sodium nitrite and 
4% new fuchsin. The napthol AS-D chloroacetate is enzymatically hydrolyzed by 




combines with a freshly formed diazonium salt, leaving bright pink color deposits 
at the site of enzymatic activity. 
C. Apoptosis  
Apoptosis was detected via terminal deoxynucleotidyl transferase biotin-dUTP nick 
end labeling (TUNEL; Millipore, Billerica, MA). In brief, formalin fixed, paraffin 
embedded liver tissue was cut at 5 μm and mounted on charged glass slides. 
Sections were deparaffinized with Citrisolv (Fisher, Waltham, MA) and rehydrated 
through graded ethanol. Tissue samples were processed according to the TUNEL 
kit protocol. TUNEL-positive cells (hepatocytes and non-parenchymal cells, NPCs) 
were counted using Image J software and are expressed as positive cells per 1000 
hepatocytes.  
D. Metabolism 
Lipid accumulation was detected via Oil Red-O (ORO) staining. Frozen sections 
of liver were cut at 10 μm and stained with Oil Red-O solution (Sigma, St. Louis, 
MO) for 10 minutes, washed, and counterstained with hematoxylin for 45 seconds. 
Samples were then mounted with Permount (Fisher, Waltham, MA). Hepatic 
glycogen reserves were visualized as a dark purple color using Periodic Acid-Schiff 
(PAS) staining. Formalin fixed, paraffin embedded liver tissue was cut at 5 μm and 
mounted on charged glass slides. Sections were deparaffinized with Citrisolv 
(Fisher, Waltham, MA) and rehydrated through graded ethanol. Sections were 
incubated in 0.5% Periodic Acid solution for 5 minutes, washed in water, and 




with hematoxylin for 45 seconds, washed in water, dehydrated through graded 
ethanol, washed in Citrisolv, and then mounted with Permount.  
IV. Immunoblots 
Liver samples were homogenized in RIPA buffer (55), containing protease and 
phosphatase inhibitor cocktails (Sigma, St. Louis, MO).  Samples were loaded onto 
SDS-polyacrylamide gels (Invitrogen, Thermo Fisher Scientific, Grand Island, NY), 
followed by electrophoresis and Western blotting onto PVDF membranes (Hybond 
P, GE Healthcare Bio-Sciences, Pittsburgh, PA). Primary antibodies against 
phosphorylated and total mTOR, total GAPDH, and total LC-3 I/II (Cell Signaling 
Technology; Beverly, MA) were used. Densitometric analysis was performed using 
UN-SCAN-IT gel (Silk Scientific Inc., Orem, UT) software. 
V. RNA Isolation and Real-Time RT-PCR 
RNA was extracted immediately following sacrifice from fresh liver samples using 
RNA Stat60 (Tel-Test, Ambion, Austin, TX) and chloroform. RNA concentrations 
were determined spectrophotometrically and 1 µg of total RNA was reverse 
transcribed using a kit (Quanta Biosciences, Gaithersburg MD).  Real-time RT-
PCR was performed using a StepOne real time PCR system (Thermo Fisher 
Scientific, Grand Island, NY).  Primers and probes were ordered as commercially 
available kits (Thermo Fisher Scientific, Grand Island, NY). The comparative CT 
method was used to determine fold differences between the target genes and an 
endogenous reference (18S).   




Results are reported as means ± SEM (n = 4-8) and were analyzed using 
SigmaPlot 11.0 (Systat Software, Inc., San Jose, CA). ANOVA with Bonferroni’s 
post-hoc test (for parametric data) or Mann-Whitney Rank Sum test (for 
nonparametric data) were used for the determination of statistical significance 
among treatment groups, as appropriate. A p value less than 0.05 was selected 


















CE exacerbates liver injury caused by ethanol  
In order to assess status of overall liver health in the given groups, plasma 
transaminase levels were measured as an index of liver injury. Figure 3A shows 
plasma transaminase levels at 4, 9, and 24 hours after CE administration. Pair-fed 
mice that did or did not receive CE showed no elevation in either ALT or AST at 
any time point. However, ethanol-fed mice who received CE show a significant 
increase in AST levels at the 24 hour time point. Figure 3B depicts representative 
photomicrographs of general liver morphology at the 9 hour time point as seen 
through H&E staining. Neither pair-fed control nor pair-fed CE animals showed 
signs of tissue damage. Ethanol-fed animals showed an increase in inflammatory 
cell infiltration. CE enhanced these effects, increasing inflammatory and necrotic 

















Figure 3. CE enhances ethanol-induced liver injury. Plasma transaminases (A) 
and representative photomicrographs for paraffin-embedded liver sections stained 
for H&E at 9 hours (B) are shown (200x). Ethanol-fed, CE administered animals 
show elevated AST levels at the 24 hour time point and damaged liver morphology 
at the 9 hour time point. a, p<0.05 compared to pair-fed controls. 
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CE enhances ethanol-induced steatosis  
Ethanol feeding is known to enhance steatosis in models of liver injury (53). In line 
with this, Figure 4 depicts lipid accumulation in the liver visualized via ORO 
staining. Pair-fed control animals showed no increase in ORO staining and CE 
alone did not significantly increase ORO positive staining. However, ethanol 
increased ORO positive staining. CE enhanced the intensity of ORO staining in 
ethanol-fed animals.  
Rapamycin blunts liver damage caused by CE and LPS 
In order to elucidate mechanisms by which CE acts as an enhancing factor in a 
multiple-hit model, a more robust model of liver injury was used with CE + LPS, as 
previously described by Anders et al., (22). To verify that rapamycin inhibited 
mTOR activation, mTOR phosphorylation was analyzed via Western Blot (Figure 
5). No significant differences were observed between the groups. To examine the 
effects of rapamycin on liver damage, plasma transaminase levels were analyzed 
(Figure 6A). Control, CE alone, and CE with rapamycin administered animals show 
normal transaminase activity. LPS alone increased ALT and AST values and CE 
enhanced this effect. Significantly, the addition of rapamycin attenuated both ALT 
and AST values. Liver morphology was examined via H&E staining and CAE 
positive cells were visualized as an index of neutrophil infiltration (Figure 6B). 
Control animals show normal morphology and little CAE positive staining. LPS 
caused inflammatory foci and an increase in CAE positive cells, CE enhanced this 
effect. Notably, rapamycin administration resulted in more normal morphology and 



















Figure 4. CE’s effect on ethanol-induced steatosis. Representative 
photomicrographs are depicted for frozen liver sections stained with ORO for lipids 
as described in Materials and Methods (200x).  
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Figure 5. Rapamycin’s effect on mTOR activity. Western Blot for 
phosphorylated mTOR and GAPDH (A) are depicted and densitometry analysis 














































































Figure 6. Rapamycin blunts liver injury caused by CE + LPS. Plasma 
transaminase levels (A) and representative photomicrographs for paraffin-
embedded livers stained with H&E and CAE (B) are shown as described in 
Materials and Methods. (200x). Data are reported at mean ± SEM. a, p<0.05 






































































Effect of rapamycin on changes in apoptosis caused by CE and LPS 
The type of cell death has been shown to play an important role in many models 
of liver injury. Indeed, previously it has been shown that VC causes necrotic rather 
than apoptotic cell death (8, 22). In order to determine the cell death pathway in 
this model of injury, TUNEL-positive cells were visualized as an index of apoptosis 
and TUNEL-positive hepatocytes and non-parenchymal cells were counted. 
Consistent with previous work with this model, an increase of TUNEL-positive cells 
with LPS administration and a decrease in that number with the addition of CE was 
observed (22). Importantly, the administration of rapamycin significantly attenuates 
the number of TUNEL-positive hepatocytes as seen in Figure 7B, while it had no 
effect on the number of TUNEL-positive non-parenchymal cells.  
Rapamycin’s effect on changes in carbohydrate and lipid metabolism caused by 
CE and LPS 
It is known that CE alone causes alterations in hepatic metabolic pathways (22). 
In order to explore the effects of mTOR inhibition on lipid and glycogen levels in 
liver tissue, ORO staining for lipids (Figure 8A) and PAS for glycogen (Figure 8B) 
were visualized. LPS alone caused an increase in ORO positive staining and a 
depletion of glycogen reserves. The combination of both CE and LPS resulted in 
enhanced ORO positive staining and almost complete depletion of hepatic 
glycogen stores. Notably, the addition of rapamycin prevented glycogen depletion 




















Figure 7. Rapamycin blunts number of TUNEL-positive cells. Representative 
photomicrographs of paraffin-embedded liver stained for TUNEL-positive cells are 
depicted (A) and positive cells were counted (B) as described in Materials and 
Methods (200x). Data are reported at mean ± SEM. a, p<0.05 compared to control, 




































































































Figure 8. Rapamycin’s effect on lipid and glycogen stores. Representative 
photomicrographs of frozen liver sections stained with ORO (top) and paraffin-
embedded liver sections stained with PAS for glycogen (bottom) are depicted as 











Rapamycin blunts CE and LPS induced inflammatory cytokine expression 
In order to determine the effect of mTOR inhibition on the inflammatory response, 
hepatic mRNA expression was analyzed to determine relative levels of pro- and 
anti-inflammatory markers. As mentioned in the introduction, TNFα is a major 
cytokine involved in liver inflammation. Plasminogen activator inhibitor-1 (PAI-1), 
a mediator of inflammation, is involved in liver injury progression (56). IL-6 and IL-
1β are pro-inflammatory cytokines involved in the acute-phase inflammatory 
response (57). Interleukin-10 (IL-10) is an anti-inflammatory cytokine and can be 
protective during liver inflammation (58). Inducible nitric oxide synthase (iNOS) is 
activated by pro-inflammatory cytokines and contributes to the inflammatory 
process (59). Across all markers, there was an increase in expression with LPS 
alone. As expected, the combination of CE and LPS enhanced expression of Tnfα, 
Pai-1, Il-6, iNos Il-1β, and Il-10. Rapamycin administration resulted in a significant 
blunting of Pai-1, iNos, Il-1β and Il-10 expression, indicating an attenuation of the 
inflammatory response. However, no significant differences were observed for 


















Figure 9. Rapamycin’s effect on inflammatory cytokines. Hepatic mRNA 
expression data for inflammatory mediators were measured by qRT-PCR are 
shown. Data are reported at mean ± SEM. a, p<0.05 compared to control, b, p<0.05 


































































































































Autophagy marker changes with CE, LPS and rapamycin  
Rapamycin’s allosteric inhibition of mTOR is known to result in an induction of 
autophagic processes (45-47). Several markers are indicative of autophagy 
progression and activation. Atg 5 is necessary for the formation and elongation of 
the autophagosome (60). Rapamycin and CE administered animals showed a 
significant increase in Atg 5 expression. LPS caused no increase in Atg5 
expression, however there was a significant increase in expression with CE and 
LPS with and without rapamycin. No differences were observed between those 
groups. Microtubule associated protein-1 light chain 3 (LC-3) is cleaved and 
conjugated to phosphatidylethanolamine to form LC-3 II which remains associated 
with the autophagosomal membrane until ultimate fusion with the lysosome (41, 
61, 62), and has been used as a marker of autophagy progression. LC-3 II protein 
was observed via Western Blot. There were no significant differences across the 
groups.  
A major target of autophagic degradation is cellular inflammatory machinery known 
as the inflammasome. Therefore, mRNA expression of a protein involved in 
inflammasome formation, NLR family pyrin domain containing 3 (NLRP3), was 
analyzed. A significant increase was observed with LPS administration. There was 
also a significant increase with CE and LPS with or without rapamycin, but no 























Figure 10. Rapamycin’s effect on autophagy markers. LC-3 protein was 
analyzed by Western Blot (A) and densitometry was used to analyze differences 
across groups (B) as described in Material and Methods. mRNA expression of 
markers of autophagy (Atg5) and inflammasome activity (Nlrp3) were measured 
by RT-qPCR (C). Data are reported as the mean ± SEM. a, p<0.05 compared to 




































































































































 Since the realization that high, occupational exposure to VC was 
hepatotoxic, workplace regulations have been implemented to avoid this severe 
type of exposure (63). However, PVC producing facilities still release VC as a 
waste product into the environment. This potentially puts the individuals around 
these facilities at risk for low-level, chronic VC exposure. As humans are rarely 
exposed to one factor at a time, other exposures, such as alcohol consumption or 
diet, may modify risk for developing more severe liver injury upon co-exposure with 
low-level VC.  
CE enhances ethanol-induced liver injury and steatosis 
 Alcohol consumption is a common risk-modifying factor for the development 
of more severe liver diseases, especially upon exposure with other modifying 
factors, such as VC. Since alcohol abuse is common in urban areas (64), the first 
goal of this project was to examine the potential risk for alcohol and low-level VC 
co-exposure using a novel model for liver injury modified from the NIAAA acute-
on-chronic model (53). In the NIAAA model, mice are given alcohol-containing diet 
for 10 days followed by a binge dose of ethanol on the final day in order to examine 
a more relevant pattern of human alcohol exposure. Here, this model was adapted 
for the purpose of examining a potential synergistic effect of two known liver-




 administered CE instead of an ethanol binge on the final day. Indeed, increased 
liver injury was observed when animals were exposed to both ethanol and CE 
(Figure 3). Chronic ethanol exposure induces its metabolizing enzyme, CYP2E1. 
(65). Acetaminophen toxicity is known to be enhanced in individuals who consume 
alcohol because the two compounds share metabolizing enzymes. Ethanol is 
preferentially metabolized by ADH, causing acetaminophen to be alternately 
metabolized to its toxic metabolite via CYP2E1, which accumulates and causes 
severe liver injury (66). However, in this model, CE is the toxic metabolite of VC 
and as such, the already induced CYP2E1 more efficiently metabolizes CE. 
Therefore, less accumulation of CE is not as damaging, resulting in less tissue 
injury and inflammation.  
Serum AST levels were significantly elevated at the 24 hour time point in 
animals who received the ethanol diet and CE, although no differences were seen 
in ALT levels at any time point. AST is known to be present in both hepatocyte 
cytoplasm and mitochondria and its isolated elevation is attributed to release from 
non-hepatic tissue, particularly damaged muscle (67). However, previous data (22) 
gives evidence that VC metabolites damage hepatic mitochondria. Therefore, the 
addition of CE to already injured hepatocytes is sufficient to cause damage to 
those mitochondria and release AST. The ratio of AST to ALT values can be a 
useful tool when determining cause of liver damage. When AST and ALT values 
respond the same, it is indicative of an acute viral or toxicant induced liver injury 
due to the release of only the cytoplasmic enzymes. However, when AST values 




to the release of the mitochondrial AST from necrotic cell death (68, 69). Therefore, 
the isolated elevated AST levels could be attributed to the ethanol-feeding alone. 
However, the addition of CE significantly enhanced AST levels compared to 
ethanol-fed control animals, suggesting a synergistic effect on liver damage. 
In ALD, steatosis is seen in 90% of subjects who consume significant 
amounts of alcohol (70). Here, steatosis was observed in ethanol-fed animals 
(Figure 4). Ethanol-fed animals mainly showed evidence of macrovesicular lipid 
droplets, being indicative of triglyceride accumulation. However, the presence of 
both micro- and macrovesicular lipid droplets was seen with the addition of CE, 
indicating an accumulation of FFA and triglycerides, respectively. The presence of 
microvesicular lipid droplets and their associated FFA have detrimental effects on 
cellular function and sensitizes the liver to be more susceptible to more severe 
injury (71). FFA accumulation has also been shown to be indicative of impaired 
mitochondrial β-oxidation (72), which is in line with previous data that VC 
metabolites are damaging hepatic mitochondria. Indeed, the addition of CE in 
ethanol-fed animals resulted in enhanced steatosis as seen by the presence of 
microvesicular lipid droplets, indicative of FFA accumulation and impaired 
mitochondrial function in this model.  
mTOR activation is critical in CE-induced liver injury 
 Exploring the interaction and possible multiple-hit phenomenon with ethanol 
and VC co-exposure resulted in interesting findings. However, we were interested 
in examining the mechanisms by which VC acts as a risk-modifying factor for 




same time in our laboratory was also employed to characterize molecular changes 
and mechanistic endpoints in response to VC metabolite exposure. In that model, 
our laboratory demonstrated that administration of the VC metabolite, CE, alone 
was sufficient to alter metabolic enzyme expression although no hepatic tissue 
damage was observed (22). With the addition of LPS administration, liver damage 
was enhanced in animals exposed to CE. Findings from that study include 
enhanced liver damage, neutrophil infiltration, oxidative stress, and metabolic 
dysfunction. Alterations of key metabolic enzymes were observed some which 
include mTOR, AMP-activated protein kinase (AMPK), and protein kinase B or 
AKT. Specifically, a significant activation of mTOR was observed in mice who were 
administered CE alone. Therefore, the second goal of this project was to 
investigate the role of mTOR in liver injury caused by VC metabolite exposure.  
mTOR inhibition blunts CE-induced metabolic changes   
 mTOR activity is known to be dysregulated in several disease states (73) 
and its inhibition has been shown to be protective in many models of liver injury 
(74, 75). A common method of mTOR inhibition involves administration of 
rapamycin. Rapamycin has anti-proliferative and immunosuppressive effects (76). 
It also enhances autophagy processes by allosteric inhibition of mTOR complex I 
(77). The metabolic profiles of animals in this experiment were analyzed 
histologically through ORO and PAS stains for lipids and glycogen, respectively. 
The addition of rapamycin blunted the accumulation of hepatic lipids and prevented 




 One possible mechanism by which rapamycin attenuated lipid accumulation 
is by affording mitochondrial protection from CE. Mitochondrial protection results 
in unhindered oxidative phosphorylation and β-oxidation. With oxidative respiration 
intact, the switch to anaerobic respiration (glycolysis) and subsequent glycogen 
depletion was not required. Additionally, Singh et al. demonstrated that autophagy 
is crucial for regulating lipid metabolism via an autophagic process unique to lipid 
droplets, lipophagy (78). Lipophagy is a specific type of autophagy in which lipid 
droplets are sequestered and enzymatically degraded by lysosomes (79). Lin and 
colleagues showed that induction of autophagy was protective against both alcohol 
and NAFLD-induced hepatic steatosis and reduced liver injury (80). Therefore, the 
results of this model of liver injury suggest that autophagic activity can blunt hepatic 
lipid droplet formation via lipophagy. FFA are known to be lipotoxic and preventing 
their accumulation would afford another mechanism of protection by rapamycin 
administration. 
mTOR inhibition attenuates CE-induced liver injury  
 Upon rapamycin administration, the liver damage and inflammation 
observed with LPS and CE was significantly attenuated (Figures 6 and 9). Chen 
et al., demonstrated in a murine model of methionine-choline deficient diet induced 
NASH, that rapamycin decreased histological damage, decreased Il-1β 
expression, and decreased myeloperoxidase activity, indicative of less neutrophil 
infiltration (84). Here, rapamycin administration significantly attenuated hepatic 
mRNA expression of inflammatory markers such as iNos, Il-10, and Il-1β. A 




Histologically, a normal gross morphology and fewer CAE positive cells were 
observed in rapamycin-administered animals, indicating that, indeed, mTOR is 
crucial for VC metabolite-induced injury. VC metabolite administration causes 
mitochondrial damage and, consequently, a decrease in cellular energy levels 
leading to cell death and injury (22). ROS and RNS, produced by damaged 
mitochondria, mediate hepatocyte inflammation and account for the increased 
injury observed. The data support that rapamycin attenuates injury via 
mitochondrial protection by increasing mitophagy. Mitophagy alleviates the burden 
of injured mitochondria within the cytoplasm by their degradation, which allows for 
maintenance of mitochondrial homeostasis and provides protection against 
enhanced damage (85). Indeed, rapamycin and CE administration caused a 
significant increase in Atg5 mRNA expression (Figure 10C), supporting the 
hypothesis of the autophagic process being active in this model.  
 In addition to its role in mediating cellular protection, autophagy is a known 
negative regulator of inflammasome activity (86, 87). Inflammasomes are multi-
protein complexes that assemble in the cytoplasm in response to pathogens or 
cellular damage (88). A major function of inflammasome formation is caspase-1 
activation and IL-1β maturation (87). The inflammasome complex NLRP3 is known 
to be activated by ROS (89) and endogenous damage signals or damage 
associated molecular patterns (DAMPs) such as high mobility group box 1 protein 
(HMGB1) and heat shock proteins (90, 91). In this study, rapamycin significantly 




elimination of excess, active inflammasomes may be important players in injury 
attenuation.  
Summary and conclusions 
 In conclusion, the current study demonstrated that VC metabolite exposure 
may be one factor in a “multiple-hit” phenomenon of liver damage in two different 
models. mTOR plays a critical role in VC metabolite-induced liver damage. Indeed, 
its inhibition attenuated indices of liver damage and steatosis. Moreover, mTOR 
inhibition caused blunting of key inflammatory mediator expression, attenuation of 
lipid accumulation and prevention of glycogen depletion. Autophagy may be a 
player in VC metabolite induced liver injury. Indeed, the data support that 
autophagy afforded mitochondrial protection via mitophagy and provided a more 
homeostatic lipid metabolic profile through lipophagy and degradation of excess, 
lipotoxic FFA. Attenuated IL-1β expression with the addition of rapamycin suggests 
that the inflammasome may be a key regulator in the progression of VC-metabolite 
induced liver injury. However, further studies are necessary to analyze these 

















Figure 11. Working hypothesis. Upon exposure to VC, 1) reactive solvent 
intermediates form though bio activation processes and diet-induced obesity 
decreases their elimination. 2) Through carbonyl stress and the generation of 
reactive oxygen and nitrogen species (ROS/RNS), solvent metabolites cause ER 
stress leading to the production of proinflammatory cytokines and mitochondrial 
damage, which impairs oxidative phosphorylation; the cell increases flux through 
anaerobic glycolysis to compensate for this loss of ATP yield. The increased 
demand for glucose depletes glycogen stores 3) acetylCoA is being shunted to 
lipid synthesis (causing steatosis) rather than β-oxidation, even under conditions 
of ATP depletion. 4) The combined metabolic stress of solvent metabolite 
exposure and ATP depletion likely causes ‘liponecrosis’ associated with increased 





































STRENGTHS OF THIS WORK  
 There are many strengths of this work. This study demonstrated that sub-
hepatotoxic levels of the VC metabolite, CE, enhanced liver damage in two 
separate models of injury. We show that underlying liver injury caused by alcohol 
is enhanced with co-exposure to CE. We also show that sub-hepatotoxic levels of 
CE can enhance injury caused by the bacterial endotoxin, LPS. Another strength 
of this work is identifying a novel role of mTOR in VC-induced liver damage. The 
hypotheses that autophagy and the inflammasome are involved in VC-induced 
liver injury are novel and this work lays a foundation for ongoing research with 
those mechanisms.  
 The use of whole animal models in this work is also a strength. All of the 
experiments here were performed in vivo. Liver injury and its mediating factors is 










PITFALLS AND FUTURE DIRECTIONS 
 Further work is needed in order to identify more detailed mechanisms 
involved in mTOR’s inhibition in VC-metabolite induced liver injury. A major 
limitation of this study is the 24 hour time point used. Future studies will be 
conducted in order to analyze mRNA expression at 4 hours post LPS 
administration, in addition to the 24 hour time point from this study. The time point 
used yielded necessary insight for establishing this model and determining 
pathology. However, an earlier time point will aid in gaining mechanistic insight to
injury progression. For example, it is foreseeable that we will see more pronounced 
changes in mTOR and LC-3 protein levels via Western Blot analysis at an earlier 
time point. Moreover, at the 4 hour time point, we expect to see more significant 
differences with the rapamycin administered mice versus CE + LPS in both mRNA 
and protein expression of inflammatory and autophagy markers. 
 Another limitation of this study was the use of the VC-metabolite, CE. 
Although CE is a primary metabolite of VC, it is not the parent compound and 
therefore may not completely recapitulate the effects seen with VC gas.  
  Future directions include expanding this model to exposing mice to VC gas 
via an inhalation chamber and a high fat diet (HFD) to induce NAFLD. This will 
better mimic human circumstances and exposures in the environment. We also 




greater depth. Lastly, we are interested in employing rapamycin in the VC-HFD 
model of liver injury to validate that mTOR is directly involved in injury progression 
and that autophagy indeed plays a crucial role in damage.  
CONCLUSIONS 
  A paradigm shift has occurred in the past years has been investigating the 
impact of low, chronic exposures in contrast to high occupational acute exposures. 
This approach attempts to take into account multiple factors and damaging agents 
that may contribute to disease status. In this context, the impact of underlying 
disorders that may modify risk is critical. Liver disease is not contributed to one 
factor, rather is modified by other mitigating conditions, such as other 
environmental or genetic factors. This study establishes that indeed, VC-
metabolite exposure can have influence over severity of liver injury when co-
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VC Vinyl chloride 
ATSDR Agency for toxic substances and disease registry 
PVC Polyvinyl chloride  
TASH Toxicant associated steatohepatitis 
FLD Fatty liver disease 
ALD Alcoholic liver disease 
NAFLD Non-alcoholic liver disease 
LPS Lipopolysaccharide 
CE Chloroethanol 
FFA Free fatty acids 




ROS/RNS Reactive oxygen species, nitrogen species 
Atg Autophagy related 
mTOR Mechanism target of rapamycin 
ALT Alanine transaminase 
AST Aspartate transaminase 
H&E Hematoxylin and Eosin 
CAE Chloroacetate esterase 
TUNEL Terminal deoxynucleotidyl transferase biotin-dUTP nick end 
labeling 
ORO Oil-Red O 
PAS Periodic Acid Schiff 
NLRP3 NLR family pyrin domain containing 3
LC-3 Microtubule associated protein-1 light chain 3 
HMGB-1 High mobility group box-1 
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